Announcement on Completion of Transfer of Manufacturing and Marketing Approval of Zomig® Tablets 2.5 mg and Zomig® RM Tablets 2.5 mg, Migraine Treatment
Osaka, Japan – June 20, 2018 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Mitsuo Sawai) today announced that it has completed the transfer of manufacturing and marketing approval of Zomig® Tablets 2.5 mg and Zomig® RM Tablets 5 mg* (generic name: zolmitriptan), a migraine treatment, as previously announced at the conclusion of its agreement with AstraZeneca (Head Office: Cambridge, the UK; CEO: Pascal Soriot) on October 4, 2017. These products will be available for sale on July 2, 2018.
- The “RM” in Zomig® RM is an acronym for “Rapid Melt.” Although this product is administered orally, as are other drugs, it is a preparation designed to melt quickly in the mouth, due to the actions of disintegrating and foaming agents within the product, whether taken with or without
Products for which the rights of manufacturing and marketing approval have been acquired:
| Therapeutic category | Name of the product |
| Migraine treatment / 5-HT1B/1D receptor agonist | Zomig® Tablets 2.5 mg
Zomig® RM Tablets 2.5 mg |
The product announced in this press release is not approved by the Food & Drug Administration for sale and distribution in the United States.
Contact information:
PR / IR Group, Corporate Strategy Department, Sawai Pharmaceutical Co., Ltd
E-mail：koho@sawai.co.jp